Thank you, of partnership to REGENXBIO summary George. information our our and our progress. clinical This XIPERE I'll related internal scientific provide and NDA R&D a resubmission, afternoon,
called into region the drugs the direct the drug and the As length. background the is delivery approach. novel to transition Suprachoroidal drug-dispensing be needle helpful the retinal proprietary cells understand about it's space. to approach injection XIPERE, on the allows and epithelial injection to choroid in employs procedure a XX-gauge a suprachoroidal provides choroid. the syringe pigment Suprachoroidal and administered sclera access injection X piston almost between millimeter The suprachoroidal retina, that
of for enhancements Clearside process. cycle Over life development made manufacturing drug course the product the quality XIPERE, to the
wants formulation process not of we the to has the drug between that the enhancements not the batches affected product. the verify product changed, suspension acetonide and While FDA stability have submitted ensure the the intended profile the triamcinolone to commercial
During to the data FDA and material in our data. in be our closely the meeting NDA manufacturing resubmission. stability with contract included working required the agency the controls been guidance or We've clear provided produce CMC to August, obtain chemistry, on the requested to and the manufacturer with
this SCS additional The final use will on Microinjector in XX that be device data the by clinical currently use CRL request expect least included also delivery approach assessment be X conducted to-be-marketed before in at conducted for believe system. We a physicians in clinicians of assessment worked FDA's a the streamlined who We can this with device. are who using recommendation. type that with and experienced per the and quick patients have us of
did mentioned clinical potential diseases and XIPERE efficacy identify multiple approval Currently, the We performed across without trials multiple there and the any results in clinical of over the were FDA X,XXX as studies future the issues, of been further events George remain to related for And CRL, XIPERE. our any studies. have suprachoroidal in significant request adverse injections confident not of the and efficacy no clinical injector.
expect the working FDA resubmission the X of prepare NDA resubmit are quarter next review requested expect with the Once data discuss believe and NDA diligently the and and and we clinical CMC, the formal will this first the a our CRL, will in within the meeting year agency, Our plans of for the plans regulatory device months of these FDA We year. confirm our the date. we to receipt the with requests generate satisfy we the have to before to for to end assessment. teams in
can and Johns Next, approach our with suprachoroidal therapy transfer the produce in partnership ocular preclinical vector several benefit species. gene expression widespread the recently AAV transgene that Hopkins field. validates at growing gene potential in team studies our further REGENXBIO Peter suprachoroidal Campochiaro's in demonstrated Dr.
showed similar administration preclinical when leakage. nonviral resulted asset, subretinal REGENXBIO's of therapeutic expression administered marker Likewise, similar of a suppression to similar of or in own and injection suprachoroidally. gene of rats, in nanoparticle DNA therapy Compared subretinally studies anti-VEGF of VEGF-induced vascular suprachoroidal protein our team activities RGX-XXX,
have SCS microinjector to opportunity the nonsurgical, proprietary excited REGENXBIO to for therapy hope onetime gene to with with the gene to our in-office AAV evaluate therapy are patients of application offering access treatment. collaborate of We the
nonclinical Internally, our therapy and on around R&D performing have experiments primarily been molecules. focused and gene discovery small efforts
enhanced XIPERE from tissues effective potential are drug choroidal suspensions clinical target delivery We that durability. the development retinal can program, for leveraging and learnings demonstrated suprachoroidal of with our molecule which efficacy prolonged small
scientific and careful shift, now prior we community, have we our have a data suspension evaluation has compelling been determined represents internal very that our strategic proceed in reviewed to assets As XIPERE presented part recently for our we of CLS-AX, the After should injection, partnered. suprachoroidal how work determine of our that successfully opportunity. axitinib of
visual retinal is of forms treat by animal VEGF a predominantly inhibiting Axitinib currently wet of ceiling inhibit receptors-X, potency cancer, more and directly -X angiogenesis existing a dosage as cell corneal, current have therapies, may Axitinib high cascade, AMD other may increased approved is and specificity. of independent retinal therapy, it over of broad -X in VEGF high Axitinib acting investigators. additional achieves been it's shown multiple by effectively with yield up-regulate With which benefit. pan-VEGF the to to on blockade different intense blockade and focus advantages choroidal with has models efficacy at angiogenesis blockade, regimens and and there VEGF VEGF. renal level no efficacy
In inhibitors. more biocompatibility than another one studies, inhibitors. with inhibit experimental ocular better kinase effectively study, of cells showed be kinase than shown receptor these axitinib In tyrosine to was neovascularization other axitinib other tyrosine corneal
significant very receiving X is undertreated, X In a treatment therapy X the in burden. with only associated improving addition, to wet injections year only and are patients current to letters. first Real-world X by AMD
as space, of with of long-acting molecule the suprachoroidal via suprachoroidal injection levels of drug axitinib's as current multiple studies decreased These to durable fluorescein leakage have reduced treatment administration, preclinical species. address growth experimental demonstrated burden. AMD as the supporting well have small suspensions potential the Given suspension suprachoroidal of assessed therapy a in durability proprietary in for axitinib we wet for a neovascularization potential
that has Based believe on meaningful suspension proprietary potential. preclinical data, of we axitinib injection, suprachoroidal our
and intrinsic axitinib First, receptor demonstrates high blockade. potency inhibition through achieves pan-VEGF
Second, And from with prolonged and experimental neovascularization preclinical of delivery fluorescein duration tissue effect suprachoroidal administration potentially Clearside reduced and effected of third, show results axitinib achieve to targeted investigators outside can and decreased growth layers. leakage. pharmacodynamic
are mid-XXXX. IND to data, working submit Based we this an CLS-AX for on in application
Over our Academy Annual of Ophthalmology we key diabetic presence data physicians with has AMD Aura worked combined additional REGENXBIO, at partnerships recent the over including presentations, and areas, have several therapeutic significantly medical or retinopathy. prominent ocular Biosciences wet deliver expanded AAO These XX American presentations and last congresses, Meeting. oncology, with months, into our with to including the
enhanced of their very and encouraged value the suprachoroidal from the approach. of We the by remain understanding community our support treatment medical
will call our over financial that, Deignan, CFO, results. now review the Charlie to Charlie? I our to With turn
